Amgen Inc. revenue by year
Over the 10 fiscal years shown, revenue went from $22.99B (year ended Dec 31, 2016) to $36.75B (year ended Dec 31, 2025), a compound annual growth rate of 5.4%. The fastest growth was +18.6% in the year ended Dec 31, 2024; the weakest year was −1.6% (year ended Dec 31, 2019).
Annual revenue
| Fiscal year ended | Revenue (USD) | Change | XBRL concept | Reported in |
|---|---|---|---|---|
| Dec 31, 2025 | $36.75B | +10.0% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 13, 2026 |
| Dec 31, 2024 | $33.42B | +18.6% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 13, 2026 |
| Dec 31, 2023 | $28.19B | +7.1% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 13, 2026 |
| Dec 31, 2022 | $26.32B | +1.3% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 14, 2025 |
| Dec 31, 2021 | $25.98B | +2.2% | RevenueFromContractWithCustomerExcludingAssessedTax | 10-K filed Feb 14, 2024 |
| Dec 31, 2020 | $25.42B | +8.8% | Revenues | 10-K filed Feb 9, 2021 |
| Dec 31, 2019 | $23.36B | −1.6% | Revenues | 10-K filed Feb 9, 2021 |
| Dec 31, 2018 | $23.75B | +3.9% | Revenues | 10-K filed Feb 9, 2021 |
| Dec 31, 2017 | $22.85B | −0.6% | Revenues | 10-K filed Feb 12, 2020 |
| Dec 31, 2016 | $22.99B | +6.1% | Revenues | 10-K filed Feb 13, 2019 |
Amgen Inc. reported revenue under 2 different XBRL concepts across these years (often after the 2018 change in revenue-recognition rules, ASC 606). Each row shows the concept used, so you can judge comparability.
Quarterly revenue
Quarters reported in 10-Q filings. Fourth quarters are usually reported only inside the annual 10-K, so they are not listed separately here; we do not estimate them.
| Quarter | Revenue (USD) | vs same quarter a year earlier | Source |
|---|---|---|---|
| 3 months ended Jun 30, 2026 | $10.05B | +9.5% | 10-Q filed Aug 5, 2026 |
| 3 months ended Mar 31, 2026 | $8.62B | +5.8% | 10-Q filed May 1, 2026 |
| 3 months ended Sep 30, 2025 | $9.56B | +12.4% | 10-Q filed Nov 5, 2025 |
| 3 months ended Jun 30, 2025 | $9.18B | +9.4% | 10-Q filed Aug 5, 2026 |
| 3 months ended Mar 31, 2025 | $8.15B | +9.4% | 10-Q filed May 1, 2026 |
| 3 months ended Sep 30, 2024 | $8.50B | +23.2% | 10-Q filed Nov 5, 2025 |
| 3 months ended Jun 30, 2024 | $8.39B | +20.1% | 10-Q filed Aug 6, 2025 |
| 3 months ended Mar 31, 2024 | $7.45B | +22.0% | 10-Q filed May 2, 2025 |
Source: SEC EDGAR XBRL company facts for CIK 318154 (raw data). Most recent filing in this dataset: 10-Q filed Aug 5, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.